FCGR3A and myelodysplastic syndrome: Currently, IPH6101/SAR443579 is the first NKp46/CD16-based NK cell engager (NKCE) using Innate’s proprietary multispecific antibody format ANKETTM in a phase I/II clinical trial (NCT05086315) in various blood cancers, such as relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL) or high risk-myelodysplastic syndrome (HR-MDS).